- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Moderna Inc (MRNA)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
183.28
193.72
52 wk Range
22.28
208.90
MRNA Comments
Compiled here, all relevant comments and discussions regarding the MRNA stock. Please note that all comments included here have met Investing.com's Comment Guidelines.
Rotate capital to $PFE
Going to 181.
I thought Kennedy was supposed to abolish Vaccine this quadruple since Trump became president
shorted
fake pump? till eom will less 100
many drug companies announced that they have found cure for cancer but their stock just has risen for few days. unlike others, modedna stock has been raising over a month and that seems a clearly stock manipulation. probably the price will go down fast was the rest results revealed by independent sources
still don't change the course
it is a Really bubble
Petr Piterskiy yes absolutely bro. just my opinion. almost all big Tech, Ai etc rally before meeting, not after meeting. make sense?
Nobody knows, but close to eoy will be much lower
Petr Piterskiy smart
Bgates and drfauci seem very based, friends
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
zero news, we knew about it from aug
Shares of Moderna, Inc. (MRNA) are gaining about 9 percent on Monday morning after the company announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology Congress.
crazy// real price 50
$160.60 (+10%)
Big opportunity for Merck to buy Moderna at 215 USD?
Today red
Moderna’s oncology pipeline looks highly promising, especially its personalized mRNA cancer vaccine intismeran autogene combined with Merck’s Keytruda. In a Phase 3 melanoma trial, the combination significantly improved recurrence-free and distant-metastasis-free survival versus Keytruda alone, potentially establishing a new personalized-treatment model. The opportunity could extend to lung, bladder, kidney, pancreatic and stomach cancers, where further trials are ongoing. However, the results are not yet equivalent to a proven overall-survival benefit, and regulatory approval, manufacturing complexity and broader trial confirmation remain important
$147.55 (+8%)
when they offer 2 billion notes, what else can it do apart from diluting the stock ?
A technology that has proven itself to deliver in crisis and now focused on cancer with FDA approval should not be dismissed. Especially in the hottest sector of the economy... Biotech is the new AI trade !
WOW
Well well well no ody wants ro buy moderna
Pre market is going RED
This Vaccine is the hit like Viagra in 1998 or even better cause it is a cancer’s cure. Pfizer shares made $ with Viagra for the shareholders. Imagine this.
the autorisation of FDA should be in the beginning of 2027 , and in Europe in the middle of 2027 , good news guys , that mean in one year 1000/action is so possible ..
up
closing at 175
falling knife
Short more!
Its falling fast
51.1 million shares traded, means, 51.3 shares were sold and bought. at the top. who had benefited ?
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.